6. Conclusions
In our preclinical study on DSS rats with hypertension, we observed that the novel ARNi drug (S086) had a significant antihypertensive effect. Its effect was superior to that of the first-generation ARNi drug LCZ696. These results support further phase 2 and phase 3 clinical studies on S086 to explore its efficacy and safety in treating patients with hypertension.
Acknowledgments: We acknowledge all supporting staffs from the Salubris and WuXi AppTec. The current work was supported by Shenzhen Science and Technology Program (Grant No. KQTD20200820151701004).
Conflict of interest statement: S086 is Salubris’ developing product, and Salubris is the patent owner.
Funding: Shenzhen Science and Technology Program (Grant No. KQTD20200820151701004)